QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
CVE:PAS

Pascal Biosciences - PAS Stock Forecast, Price & News

C$0.02
-0.01 (-25.00%)
(As of 12/5/2022)
Add
Compare
Today's Range
C$0.02
▼
C$0.02
50-Day Range
C$0.02
▼
C$0.02
52-Week Range
C$0.02
▼
C$0.10
Volume
4,000 shs
Average Volume
52,289 shs
Market Capitalization
C$983,925.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PAS stock logo

About Pascal Biosciences (CVE:PAS) Stock

Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington.

Receive PAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pascal Biosciences and its competitors with MarketBeat's FREE daily newsletter.

PAS Stock News Headlines

February 3, 2023 | msn.com
Pedro Pascal Nearly Kills a Mysterious New ‘Saturday Night Live’ Cast Member in This Week’s Promo
February 3, 2023 | msn.com
Pedro Pascal’s Girlfriend History: Meet The Women He’s Been Romantically Linked To Over The Years
February 3, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
February 3, 2023 | msn.com
Pedro Pascal Reminds Us Why He’s Daddy By Twerking With Clicker from ‘The Last of Us’ in 'SNL' Promo
February 3, 2023 | msn.com
'The Last of Us' star Pedro Pascal's San Antonio connection
February 2, 2023 | msn.com
Pascal Siakam Snubbed of All-Star Spot as League Announces Reserves
February 2, 2023 | msn.com
Raptors’ Pascal Siakam All-Star snub gets hilarious one-emoji reaction by Fred VanVleet
February 2, 2023 | msn.com
Watch Pedro Pascal grooving to Latto and Mariah Carey’s song ‘Big Energy’ on SNL
February 3, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
February 2, 2023 | msn.com
Watch: Pedro Pascal confronts a clicker in 'SNL' promo
February 2, 2023 | msn.com
San Antonio claims 'The Last of Us' actor Pedro Pascal ahead of 'SNL' debut
February 2, 2023 | msn.com
Pedro Pascal Can’t Kill a ‘Last of Us’ Clicker in ‘Saturday Night Live’ Promo
February 1, 2023 | msn.com
Pedro Pascal Faces Another ‘The Last of Us’ Clicker in ‘SNL’ Promo (VIDEO)
February 1, 2023 | msn.com
Pedro Pascal Parodies The Last of Us in First Saturday Night Live Promo
February 1, 2023 | msn.com
Pedro Pascal Is Clicker-Bait In New ‘SNL’ Promo
February 1, 2023 | msn.com
FE: Pascal Wehrlein explains surprise at Porsche's stunning start to season
January 31, 2023 | msn.com
Raptors Rumors: Gary Trent Jr, OG Anunoby, Fred VanVleet, Pascal Siakam, Nick Nurse
January 31, 2023 | msn.com
Unforgettable weekend in Diriyah leaves Pascal Wehrlein at the top of Formula E>
January 30, 2023 | msn.com
Unforgettable weekend in Diriyah leaves Pascal Wehrlein at the top of Formula E
January 30, 2023 | msn.com
Pedro Pascal’s net worth in 2023
January 30, 2023 | msn.com
WATCH: Porsche's Pascal Wehrlein takes the Formula E lead in nail-biting Saudi race
January 30, 2023 | msn.com
Inside Pascal Siakam's All-Star case: Is Raptors forward a shoo-in for 2023 in Utah?
January 28, 2023 | msn.com
Pascal Wehrlein's double Formula E triumph in Diriyah
January 28, 2023 | msn.com
FE: Double Diriyah delight for Pascal Wehrlein in Saudi Arabia
January 28, 2023 | msn.com
The Last of Us: Pedro Pascal and Bella Ramsey Quiz Each Other in New Video
January 28, 2023 | msn.com
Pascal Wehrlein led Porsche to victory in Diriyah
January 27, 2023 | msn.com
Pedro Pascal's The Last of Us has been renewed for a second season
See More Headlines
Receive PAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pascal Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
CVE
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
CVE:PAS
CUSIP
N/A
CIK
N/A
Web
www.biommune.net
Phone
+1-604-6886775
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
882.79
Current Ratio
0.18
Quick Ratio
0.17

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
C$0.00 per share
Price / Cash Flow
55.00
Book Value
C($0.01) per share
Price / Book
-1.36

Miscellaneous

Outstanding Shares
65,595,000
Free Float
N/A
Market Cap
C$983,925.00
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Harold H. Forzley C.A. (Age 69)
    Chief Financial Officer
    Comp: $16.8k
  • Dr. Brian W. Bapty Ph.D. (Age 53)
    CEO, Pres & Director
  • Mr. Kevin M. Egan M.B.A.
    Chief Bus. Officer

Key Competitors

View All Competitors













PAS Stock - Frequently Asked Questions

How have PAS shares performed in 2023?

Pascal Biosciences' stock was trading at C$0.02 at the beginning of the year. Since then, PAS shares have increased by 0.0% and is now trading at C$0.02.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Pascal Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pascal Biosciences investors own include Aurora Cannabis (ACB), Canadian Natural Resources (CNQ), Corus Entertainment (CJR), Auxly Cannabis Group (CBWTF), Grande West Transportation Group (BUS), Bausch Health Companies (BHC), Abattis Bioceuticals (ATT), Algonquin Power & Utilities (AQN), Aphria (APHA) and Abacus Mining & Exploration (AME).

What is Pascal Biosciences' stock symbol?

Pascal Biosciences trades on the Canadian Venture Exchange (CVE) under the ticker symbol "PAS."

How do I buy shares of Pascal Biosciences?

Shares of PAS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Pascal Biosciences' stock price today?

One share of PAS stock can currently be purchased for approximately C$0.02.

How much money does Pascal Biosciences make?

Pascal Biosciences (CVE:PAS) has a market capitalization of C$983,925.00.

How can I contact Pascal Biosciences?

Pascal Biosciences' mailing address is 400 Burrard St Suite 1780, VANCOUVER, BC V6C 3A6, Canada. The official website for the company is www.biommune.net. The company can be reached via phone at +1-604-6886775.

This page (CVE:PAS) was last updated on 2/3/2023 by MarketBeat.com Staff